Open AccessPhase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Author(s) -
Makoto Aihara,
Fenghe Lu,
Hisashi Kawata,
Akihiro Iwata,
Kathy Liu,
Noriko Odani-Kawabata,
Naveed Shams
Publication year - 2019
Publication title -
journal of glaucoma
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.11
H-Index - 88
eISSN - 1536-481X
pISSN - 1057-0829
DOI - 10.1097/ijg.0000000000001221
Subject(s) - latanoprost , medicine , tolerability , intraocular pressure , ocular hypertension , glaucoma , clinical endpoint , placebo , open angle glaucoma , ophthalmology , adverse effect , randomized controlled trial , anesthesia , alternative medicine , pathology
PRéCIS:: Three randomized, multicenter studies demonstrated the stable intraocular pressure-lowering effects and tolerability of omidenepag isopropyl in patients with primary open-angle glaucoma and ocular hypertension; 0.002% was identified as the optimal dose for further investigation.